Clinical Trials Logo

Alveolitis clinical trials

View clinical trials related to Alveolitis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00512902 Completed - Systemic Sclerosis Clinical Trials

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis

Start date: August 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of imatinib (gleevec) in subjects who have systemic sclerosis. Imatinib has been approved by the FDA for the treatment of newly diagnosed adult patients with CML (newly diagnosed adult patients and for the treatment of patients with an accelerated phase. Imatinib is also approved for the treatment of patients with a certain type of gastrointestinal cancer (called stromal tumors) but it has not been approved to treat systemic sclerosis. Imatinib works by interfering with an enzyme called tyrosine phosphatase resulting in suppression of the immune system. It als interferes with a protein called platelet derived growth factor receptor (PDGFr) that has been linked to increased fibrosis.